Pregnancy Reduces COVID-19 Vaccine Immunity Against Novel Variants

Maclaine A. Parish[1], Jaiprasath Sachithanandham[1], Lizeth Gutierrez[2], Han-Sol Park[1], Anna Yin[1], Katerina Roznik[2], Patrick Creisher[1], John S. Lee[1], Laura A. St Clair, [1] Annie Werner[1], Catherine Pilgrim-Grayson[4], Lea Berhane[5], Hana Golding[6], Patrick Shea[1], Katherine Fenstermacher[7], Richard Rothman[7], Irina Burd[8], Jeanne Sheffield[9], Andrea L. Cox[1,2], Andrew Pekosz[1,2,7], and Sabra L. Klein[1,2*]

[1]W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

[2]Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA

[4] Division of Rare Diseases and Medical Genetics; Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research; U.S. Food and Drug Administration, Silver Spring, MD, USA

[5]Division of Clinical Policy, Office of New Drug Policy, Office of New Drugs; Center for Drug Evaluation and Research; U.S. Food and Drug Administration, Silver Spring, MD, USA

[6]Division of Viral Products, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

[7]Department of Emergency Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

[8]Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD, USA

[9]Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD, USA

*Address correspondence to Sabra L. Klein, (410)955-8898, sklein2@jhu.edu

Abstract

Pregnant women are at heightened risk for severe outcomes from infectious

diseases like COVID-19, yet were not included in initial vaccine trials, which may contribute

to low booster uptake (15% or lower). We explored the serological and cellular responses

to COVID-19 mRNA booster vaccines (i.e., ancestral and BA.5) in pregnant and age-

matched, non-pregnant females to identify how pregnancy affects immunity against

vaccine and novel variants. Antibodies from pregnant women were less cross-reactive to

non-vaccine antigens, including XBB.1.5 and JN.1. Non-pregnant females showed greater

IgG1:IgG3 ratios and neutralization against all variants. In contrast, pregnant women had

lower IgG1:IgG3 ratios and neutralization but increased antibody-dependent NK cell

cytokine production and neutrophil phagocytosis, especially against novel variants.

Pregnancy increased memory CD4+ T cells IFNγ production, monofunctional dominance,

and fatty acid oxidation. Pregnancy may reduce the breadth, composition, and magnitude

of humoral and cellular immunity, particularly in response to novel variants.

Introduction

Pregnant women faced significant morbidity and mortality during the COVID-19 pandemic, with an elevated risk for severe outcomes [1-3]. From the onset of the pandemic in early 2020 to December 2022, there were 24,203 cases of COVID-19 among pregnant women in the United States with 2,043 fatalities [4]. This 8.4% mortality rate is significantly higher than that of the general population (0.061%), reflecting the elevated risk for disease outcomes in pregnancy. Pregnant women also were more likely to require hospitalization and invasive ventilation from acute SARS-CoV-2 infection than non-pregnant women [3, 4]. Adverse pregnancy and neonatal outcomes were an additional concern, as SARS-CoV-2 infection has been associated with preeclampsia, stillbirth, NICU admission, and preterm birth in women [1, 5-9] and mouse models [10].

American College of Obstetricians and Gynecologists (ACOG) recommend vaccination during pregnancy to provide optimal protection against SARS-CoV-2 for both the mother and fetus [11]. Data from November 2021 show vaccination rates among pregnant women (45.1%) were significantly lower than that of non-pregnant individuals (64.9%) [12]. Vaccination rates among pregnant women have since fallen precipitously, and remain lower than the general population, with less than 15% of pregnant women vaccinated in the 2023-2024 vaccination season [13]. This decline in vaccine uptake is particularly concerning given that other vaccines offered during pregnancy, such as influenza and Tdap, show higher coverage rates (47.4% and 59.6%, respectively) [14, 15]. Despite a favorable benefit of administering COVID-19 vaccines during pregnancy [16-18], low vaccine uptake may be a result of greater vaccine hesitancy in this population [19-24].

While vaccination is the best preventative strategy to reduce the severity of COVID-

19 outcomes [16, 25], existing evidence suggests pregnant women mount dampened

immune responses to vaccination, highlighting the need for deeper immunological

assessments [26]. While evidence investigating the immunogenicity of COVID-19 vaccines

in pregnant women showed effective neutralizing antibody responses to primary mRNA

vaccine two-shot series and efficient maternal antibody transfer via cord blood [27-29],

data on cross-protection elicited by vaccination are limited. Previous studies of COVID-19

vaccines in pregnant women have focused on placental antibody transfer, demonstrating

the benefits of maternal vaccination in protecting newborns and infants from severe

infection [30-32]. While several studies have aimed to compare the antibody landscape

induced by vaccination during pregnancy with those in non-pregnant women [33], to date,

the effects of pregnancy on cross-protection against circulating variants in addition to

vaccine antigens have remained unexplored.

Using systems serology, we can broadly and deeply characterize the antibody

landscape in response to COVID-19 vaccination. By employing this systematic and

comprehensive approach, we can gain insight to shape future vaccine development and

public-health campaigns by understanding the protective immune response generated by

vaccination [34]. Combining functional assays and systems serology methods, we show

that the breadth and diversity of antibody generated by vaccination and polyfunctionality of

spike-specific memory CD4+ T cells are reduced during pregnancy.

Results

Pregnancy alters IgG subtype dominance in response to novel variants

Because SARS-CoV-2 nucleocapsid (N) antibodies are not generated by mRNA

vaccines targeted to S protein, this can be used as a proxy for SARS-CoV-2 infection [46],

with recognized limitations [37]. There was no increase in either anti-N IgG **(Figure 1A)** or in

any subclass of IgG1-4 **(Supplemental Figure 1A)** in any participants, suggesting that no

one was infected with SARS-CoV-2 during their study enrollment window. However, all

participants had detectable anti-N IgG levels highlighting prior exposure to SARS-CoV-2 in

our cohort. Luminex-bead assays were used to comprehensively characterize the antibody

response generated by vaccination against SARS-CoV-2 vaccine antigens (ancestral and

BA.5 S) and circulating variants (XBB.1.5 and JN.1 S). COVID-19 boosters induced IgG in

both pregnant and non-pregnant females to circulating variants **(Figure 1B)**. Similar to anti-

N IgG, prior to vaccination, total IgG to ancestral S and BA.5 S was high in both cohorts, as

SARS-CoV-2 exposure through infection and prior vaccination is pervasive in the general

population [47]. This was reflected by limited increase in anti-S IgG responses to vaccine

variants (ancestral and BA.5) as pre-existing immunity was high at baseline. In contrast,

anti-S IgG increased in response to novel variants (XBB.1.5 and JN.1) likely as a result of

lower pre-existing immunity. There were, however, distinct differences in the IgG subtype

dominance across groups. When comparing relative isotype abundance, there was IgG1

subtype dominance among non-pregnant, but not pregnant, females, particularly in

response to JN.1 (p = 0.04) **(Figure 1C-F).** While IgG3 contributed to a small proportion of

total IgG generated in response to vaccination, pregnant women were more likely to induce

anti-S IgG3 than non-pregnant females, particularly against BA.5, while non-pregnant

women were more likely to induce IgG4 **(Supplemental Figure 1 B-E).** Non-pregnant

women induced anti-S IgG4 responses against all variants. While this is atypical for

traditional vaccine responses, evidence in the literature suggest this may be a signature of

immune imprinting from subsequent vaccination with mRNA boosters [48]. While not

investigated here, it has been suggested that this may be evidence of immune tolerance

and may be related to incidence of breakthrough infection [48, 49].

Pregnancy reduces the cross-neutralizing capacity of antibodies recognizing SARS-

CoV-2 variants

The ratio of IgG1:IgG3 has been shown to be predictive of SARS-CoV-2 neutralization

capacity [50]. Compared with non-pregnant females, pregnant women had reduced

IgG1:IgG3 ratios, particularly to novel variants, (JN.1 $p = 0.02$, XBB.1.5 $p = 0.05$) suggesting

that the dominant IgG1 response in non-pregnant females may be indicative of broader

cross-neutralization **(Figure 2A-D).** This was reflected by reduced neutralizing antibody

(nAb) titers in pregnant compared with non-pregnant women to variants (JN.1 $p = 0.07$,

XBB.1.5 $p = 0.03$). Both cohorts showed a rise ($p < 0.001$) in nAb titers to ancestral and BA.5

viruses after vaccination and were able to effectively neutralize these viruses **(Figure 2E-F)**.

Pregnant women, however, had significantly lower nAb titers than non-pregnant females,

with many pregnant women failing to reach the limit of detection **(Figure 2E-H)**. In response

to XBB.1.5, while vaccination significantly increased nAb titers in both groups, these

responses were significantly higher in non-pregnant than pregnant females, with 43% (3/7)

of pregnant women failing to reach detectable nAb titers in comparison to 15% (2/13) of

non-pregnant women. Likewise, among non-pregnant females, vaccination boosted nAb

titers against JN.1; there was, however, no vaccine-induced increase in nAb titers among

pregnant women, with only 28% (2/7) surpassing the limit of detection. **(Figure 2G-H)**. This

is further reflected by modest positive correlations between neutralizing antibody titers and

IgG1/IgG3 ratios, among non-pregnant women **(Figure 2J-L),** suggesting their increased

IgG1/IgG3 ratios may contribute to the increased neutralizing capacity in comparison to

pregnant females, even with small sample sizes**.** These data suggest that there is reduced

breadth and cross-reactivity to variants after COVID-19 boosting among pregnant

compared with non-pregnant females. A reduction in neutralizing antibody titer, potentially

facilitated by a shift in isotype dominance may contribute to reduced protection from

vaccination during pregnancy.

Fc receptor binding is not increased in pregnant women against novel variants

139   While nAb titers are considered a correlate of protection for SARS-CoV-2 infection

[51-53], non-neutralizing functions are also important and may contribute to robust

protection from severe disease [54]. Data from mouse models suggest FcR-binding and its

associated effector functions are necessary for preventing severe COVID-19 disease [55].

To further understand the depth and breadth of antibody generated by mRNA boosters in

pregnant women, we investigated FcR binding. Antibody Fc binding to FcγRIIA-R, FcγRIIA-

H, FcγRIIb, FcγRIIIA-V, FcγRIIIA-F, FcγRIIIB, FcRn, and FcαR was assessed by a multiplexed

Luminex bead assay. FcR binding was similarly induced by vaccination in response to

ancestral and BA.5 vaccine antigens among both non-pregnant and pregnant females

(Figure 3A-B). While non-pregnant females showed similar increases in FcR binding to

non-vaccine antigens following vaccination, vaccination did not induce robust changes in

FcR binding in pregnant women, with increased binding to only 2/6 FcγRs in response to

XBB1.5 and 4/6 FcγRs in response to JN.1 (**Figure 3C-D**).

Non-neutralizing antibody functions and nAb are negatively correlated among

pregnant women

To understand how FcR binding contributes to immunity generated by COVID-19

vaccination, several non-neutralizing antibody functions were assessed. Non-neutralizing

functions aid in the clearance of infected cells through recruitment of effector cells [56].

Antibody-dependent complement deposition (ADCD) was analyzed with a multiplexed

Luminex bead assay to measure antibody binding to complement protein C3 as a broad

indicator of the ability of serum antibody to induce activation of the complement cascade

[42]. ADCD was induced by vaccination in both cohorts in response to only XBB.1.5.

(**Figure 4A**). ADCD to ancestral and BA.5 S was high in pre-vaccination samples suggesting

high preexisting immune responses through complement activation in both cohorts. Non-

pregnant females had decreased post vaccination ADCD to JN.1, which was significantly

lower than pregnant females which were unchanged by vaccination. These data highlight

the differences between variants and how virus evolution may dictate the type and function

of antibody generated in response to vaccination. XBB.1.5 and JN.1 are distinct lineages

originating from BA.5 that harbor many mutations on the spike protein which can alter the

ability of the virus to evade distinct immune functions [57]. While both variants have

evolved antibody evasion strategies, these data suggest they may be leveraged through

different mechanisms.

In pregnancy, macrophage inflammatory protein (MIP)-1β+ NK cells are found at the

maternal-fetal interface and are important for successful implantation and placentation

[58]. In NK cells, MIP-1β acts as a chemoattractant in response to activation [59]. Antibody-

dependent NK-cell cytotoxicity (ADNK) can be measured through MIP-1β production by NK

cells [60]. Although neither cohort induced additional MIP-1β secretion against ancestral,

BA.5, or XBB.1.5 following vaccination, MIP-1β+ NK cells were uniquely elevated in

pregnant women following vaccination when compared with non-pregnant females (**Figure**

4B). In NK cells, interferon gamma (IFNγ) acts as an antiviral cytokine to promote further

accumulation, activation, and cytotoxicity of NK cells [61]. As an additional readout of

ADNK, NK cell IFNγ production post-vaccination was elevated in pregnant women in

response to BA.5 and in non-pregnant females in response to JN.1 **(Supplemental Figure**

3A). There were no changes post-vaccination in NK-cell degranulation, as marked by

CD107a+ NK cells, among either cohort **(Supplemental Figure 3B)**. While vaccination did

not increase ADNK capacity to vaccine antigens in either cohort, elevated ADNK in

pregnant women in comparison to non-pregnant women may be important for

understanding the antiviral and functional capacity of antibodies generated by vaccination.

Antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent

neutrophil phagocytosis (ADNP) assess the ability of antibody to induce macrophage and

neutrophil phagocytosis of antigen, respectively, and are reported as a PhagoScore [43],

representing both the function and number of beads phagocytosed. While inconsistent

across variants and groups, ADCP tended to decrease among non-pregnant women while

no changes in PhagoScores were observed in pregnant women. ADNP followed a similar

trend among non-pregnant women. Among pregnant women, however, ADNP decreased

against ancestral and JN.1 antigens while there was no change in response to either BA.5

or XBB.1.5 post vaccination (**Figure 4C**). This is likely indicative of shifting dynamics

between neutralizing and non-neutralizing functions, a phenomenon that has been

documented in the context of repeat vaccination and may be a result of immune imprinting

mechanisms [62]. Correlation analyses revealed significant negative correlations between

nAb titers and ADNP PhagoScores among pregnant women only, further suggesting a shift

away from neutralization, and towards non-neutralizing neutrophil phagocytosis among

pregnant women (**Figure 4E-H**). For JN.1, correlation analyses were non-significant likely

because responses from many pregnant women were below the limit of detection for nAb

titer (**Figure 4H**). In non-pregnant females, while negative correlations between nAb titers

and ADNP were seen in response JN.1, ancestral, BA.5 and XBB.1.5, these associations

were non-significant, suggesting small sample sizes may preclude strong conclusions.

Altered correlations among IgG subclasses and antibody functional phenotypes in

pregnant women

Correlation matrices can be used to examine complex relationships between

antibody isotypes and effector functions assessed by systems serology [63]. These

analyses can highlight isotype dependence and may reveal differences in subclass

functionality [63]. Spearman correlation matrices were generated to assess correlations

between IgG isotypes and FcR binding and antibody functional properties prior to and in

response to vaccine and variant viruses (**Figure 5**). Prior to vaccination, there was no IgG

subtype dominance, but there were stronger positive associations between IgG subclasses

and antibody functional outcomes, including in response to variants (**Figure 5A**). Matrices

of post-vaccination samples were most different between pregnant and non-pregnant

women for variants, with fewer strong correlations in pregnant than non-pregnant women.

Among non-pregnant women, anti-S IgG1 was positively and anti-S IgG3 was negatively

correlated with FcR binding as well as neutralizing and non-neutralizing antibody functions,

particularly against variants. This trend was reversed in pregnant women, in which anti-S

IgG3 was positively and anti-S IgG1tended to be negatively correlated with Fc receptor

binding and functional outputs. These data further implicate the reduced IgG1:IgG3 ratio

and isotype subclass switching as functionally altering antibody-mediated immunity in

pregnant women.

Decreased polyfunctional CD4$^+$ T cells responses in pregnant women

Because immunoglobulin subtype switching depends on CD4$^+$ T-cell help and

cytokine production [64], we hypothesized that differences in CD4$^+$ T-cell cytokine

production between pregnant and nonpregnant females may contribute to differences in

isotype switching and IgG subtypes. We assessed intracellular-cytokine production by

memory CD4$^+$ T cells **(Supplemental Figure 3A)** and CD8$^+$ T cells **(Supplemental Figure**

4A) in pregnant and non-pregnant women in response to ancestral S-peptide pools [65, 66]

prior to and after vaccination by measuring IFNγ, TNF, IL-2, and IL-21 secretion

(Supplemental Figures 3B, 4B). While individual cytokine frequencies provided initial

insight into S-specific CD4$^+$ memory T cell responses, comprehensive assessment of T cell

functionality requires analysis of polyfunctional responses. Polyfunctionality is defined as

the ability for individual cells to produce more than one cytokine simultaneously [67]. This

approach is particularly important considering preliminary analysis of limited class-

switching in pregnant participants, with polyfunctional CD4$^+$ T-cell responses being known

to enhance nAb titers and immunity following vaccination against multiple pathogens,

including SARS-CoV-2 [68-70]. To characterize the functionality of CD4$^+$ T cell responses,

Boolean gating analysis identified all (15) possible combinations of the four measured

cytokines represented as pie charts (**Figure 6A-B**) or histograms (**Supplemental Figure 5**).

Intracellular cytokine staining of CD4$^+$ T cells in response to ancestral S-peptide

stimulation at post-vaccination timepoints suggested differences in cytokine profiles

between groups **(Figure 6).** While both pregnant and non-pregnant women had IFNγ+

monofunctional CD4$^+$ T cells, pregnant women tended to have proportionally higher

frequencies of these cells. In CD4$^+$ T cells, IFNγ production is known to modulate class

switching in B cells, particularly favoring IgG3 over IgG1 [71-73]. Non-pregnant women

showed a trend toward greater CD4$^+$ T cell polyfunctionality, with more cells co-expressing

multiple cytokines including IL-21, TNF and IL-2 (**Figure 6B**), cytokines that influence B cell

maturation and antibody production. IL-2 is essential for T cell proliferation and survival,

particularly supporting the development and maintenance of T follicular helper (Tfh) cells

for germinal center reactions [74]. TNF contributes to germinal center formation and

promotes B cell differentiation and isotype switching [75, 76]. Our analysis revealed that

TNF production was enhanced in memory CD4$^+$ T cells from pregnant but not non-pregnant

females after vaccination. Alterations in polyfunctionality of T cells, and decreased

production of these cytokines may contribute to the diminished cross-neutralizing

antibody responses and altered IgG subclass distribution among pregnant women. In

contrast, no effects of pregnancy or vaccination were observed in intracellular cytokine

responses to S in memory CD8$^+$ T cells (**Supplemental Figure 6**).

Carnitine palmitoyltransferase 1A (CPT1a) expression is elevated* in *T cells of pregnant

women

To further investigate phenotypic differences in T cells from pregnant and non-

pregnant women, data generated by UMAP (Uniform Manifold Approximation and

Projection) and clustering analysis were analyzed for shifts pre- and post-vaccination in

both groups. There were no differences in any markers of activation, exhaustion, and

metabolism (**Supplemental Table 1**) pre- or post- vaccination between pregnant and non-

pregnant except for carnitine palmitoyl transferase 1 A (CPT1a), the rate limiting enzyme in

long chain fatty acid oxidation (FAO) [77]. CPT1a was greater in both CD4$^+$and CD8$^+$T cells

prior to vaccination among pregnant compared with non-pregnant females (**Figure 7A-F**).

Quantitative analysis of CPT1a mean fluorescence intensity [78] in memory CD4$^+$ T cells

revealed that pregnant females maintained approximately 1.5-fold higher expression

(31,646 ±,1,372) compared to non-pregnant females (22,885 ± 1,587) prior to and after

vaccination **(Figure 7A-B).** This was also seen in the pre-vaccination timepoint for CD8+

memory T cells **(Figure 7D).** This is consistent with prior literature showing that gestational

changes increase fatty acid availability to T cells [79]. After vaccination CPT1a was reduced

in total and memory CD4$^+$ T cells (**Figure 7C-D**), but not in either total or memory CD8+ T

cells (**Figure 7E-F**) among pregnant females. In contrast, CPT1a remained constant after

vaccination among non-pregnant females.

Discussion

Through broad characterization of the antibody landscape following COVID-19

vaccination, pregnancy was associated with reduced cross-reactive antibody responses,

reflected in decreased IgG1:IgG3 ratios, nAb titers, and FcR-binding in pregnant compared

with non-pregnant women. Previous studies have assessed the antibody profile generated

by COVID-19 vaccination during pregnancy [31, 33, 80], with a focus on transplacental

antibody transfer and protection of babies and infants from severe disease. One study

showed limited cross-recognition in pregnant women to non-vaccine antigens after the first

doses of ancestral vaccines, without comparison to non-pregnant controls nor assessment

of neutralizing responses [31]. Our data illustrate that pregnancy is associated with

reduced breadth and lower nAb responses to variants as compared with non-pregnant

controls. Continuing efforts to assess antibody responses to updated vaccines remains

critical to understanding cross-protection to variants in circulation.

SARS-CoV-2 has continued to rapidly evolve and mutate into new variants to escape

adaptive-immune responses [81]. In 2022, Omicron variants became dominant in

circulation, largely due to an ability to evade nAb generated by ancestral vaccines and

natural infections [82]. New variants with the ability to evade nAb continue to emerge and

dominate, with XBB.1.5. appearing in October 2022 and peaking in January of 2023, after

the inclusion of BA.5 in bivalent booster vaccines was established [83]. By the time XBB.1.5

monovalent boosters were accessible, a new variant, JN.1 caused 60% of global cases [83,

84]. A potential limitation of annual vaccines is mismatches between dominant circulating

strains and updated booster vaccines because variants continue to emerge between

annual vaccines strain updates [85-87]. While mRNA technology has increased the speed

in which companies can adapt updated vaccines to emerging variants, development of a

new booster vaccine still takes several months [88]. Thus, government officials and

researchers must work collaboratively to select strains for booster vaccines that will elicit

the greatest breadth of immunity [88]. In our study, almost all women were vaccinated

against ancestral and BA.5 (bivalent boosters), while XBB.1.5. was the dominant variant in

circulation. Our data suggest that pregnancy may limit cross-protective antibodies.

Retrospective chart analysis shows that pregnant women are at an elevated risk for

breakthrough infection [89]. Similar risk has been shown for other immunologically unique

groups including solid-organ transplant recipients and those with autoimmune disease

[89]. Thus, our findings of reduced cross-reactive and cross-neutralizing antibodies may

provide insight into the mechanism driving elevated risk for breakthrough infection among

vulnerable populations.

With repeated exposure to antigen through natural infection and booster vaccines,

antibody responses to COVID-19 vaccines have evolved and correlates of protection have

changed. Total IgG and nAb titers are considered adequate correlates of protection against

COVID-19, similar to other acute respiratory infectious diseases [90]. Recent data have

suggested that to mount sufficient protection, antibodies against SARS-CoV-2 must

possess both neutralizing and non-neutralizing functions as correlates of protection [91].

As nAb titers wane and symptomatic cases rise, hospitalization rates among the general

population remain low [92]. This provides evidence that other antibody characteristics may

be important for protection from severe disease. Our data demonstrate that pregnant

women have reduced FcR binding and nAb responses combined with elevated ADNK,

especially to non-vaccine antigens.

Pregnancy is known to alter antibody glycosylation patterns which can dramatically

affect their ability to efficiently and effectively interact with Fc receptors [93, 94]. Structural

changes to the antibody-receptor interaction during pregnancy drives nuanced functional

consequences that alter cross-reactivity and potentially cross-protection, generated in

response to vaccination [93, 94]. In the context of SARS-CoV-2, non-neutralizing antibodies

capable of inducing NK cell cytotoxicity were preferentially transferred across the placenta

rather than nAb and was driven by differences in antibody glycosylation patterns [95].

Future work characterizing antibody glycosylation patterns in pregnant and non-pregnant

women could shed light on the mechanisms by which pregnancy alters cross-reactive

antibody responses.

Our data suggest that reduced class switching and T-cell polyfunctionality may

contribute to limited cross-reactivity of antibodies during pregnancy. CD4$^+$ T cells are

critical for generation of high affinity, class switched antibodies and contribute to vaccine-

induced protection against COVID-19 [96]. Expansion of IFNγ+ monofunctional CD4$^+$ T

cells may contribute to reduced IgG1:IgG3 ratios among pregnant women, as these cells

may promote IgG3 bias in B cells [71-73]. The observation of a pregnancy-associated

metabolic shift toward enhanced FAO compared to non-pregnant participants may reflect

a complex dynamic of baseline metabolic reprogramming during pregnancy that may alter

vaccination-induced immune responses. Maternal circulation provides a fatty acid-rich

environment during the third trimester [79]. The increased expression of CPT1a supports

the ability of T cells to use FAO as an energy source in pregnancy. FAO influences the

differentiation of CD4$^+$ T cells into different subsets, but the impact of increased FAO on

polyfunctionality is not well understood [97, 98]. The small sample sizes in our T cell

analyses (N=3 non-pregnant, N=7 pregnant) limit the generalizability of our findings and

statistical power to detect meaningful differences. However, despite these small numbers,

a statistically significant increase in T cell CPT1a expression provides additional insights

into the impact of a fatty acid rich environment in pregnancy. Additional investigation into

how this may impact CD4$^+$ T cell polyfunctionality could provide mechanistic insights into

pregnancy-associated immune adaptations and highlight the importance of larger studies

to confirm these preliminary observations and establish clinical significance to better

inform vaccine adherence in the context of pregnancy.

While not studied here, maternal antibody transfer is a critical aspect of vaccination

during pregnancy, and our data may have implications in our understanding of the

protection provided to neonates via cord blood. In fact, a study assessing newborn

antibody found that the total number of maternal vaccines received in addition to the

timing of the most recent vaccination was a strong predictor of nAb in neonates [99].

However, data on the cross-reactivity and cross-protection of these maternally transferred

antibodies is lacking. Data from pregnant women and their neonates receiving the primary

vaccination series suggest limited Omicron specific IgG and FcR binding [31]. This suggests

our data may translate to reduced neonatal protection from maternal antibody transfer.

Prior immunization and infection history is an important contributor to immune

responses following vaccination and was not analyzed here due to low sample size. In our

cohort, there was large amounts of pre-existing immunity reflected by high pre-vaccination

levels to a variety of measures including total IgG. Unfortunately, we were unable to directly

assess the impact of prior exposures as vaccination and infection records were not

available for either cohort of participants. As such it is important to consider the role of

immune imprinting when considering cross-reactive and cross-protective antibodies

generated through vaccination as immune history may direct the breadth and depth of

antibody responses [62]. From data in non-pregnant individuals, immune imprinting is

shown to significantly limit the ability of B cells to generate antibody responses to vaccine

variants following primary vaccination series [100]. This is an important consideration,

particularly as our data suggest pregnancy limits the cross-reactive antibody response and

may be further influenced by immune imprinting mechanisms.

Although participants in the pregnant and non-pregnant cohorts were age-matched,

small sample size limited our ability to consider other demographic variables and impacts

the generalizability of our findings. For example, previous studies have shown the impact of

trimester on immune responses generated by COVID-19 vaccination [16, 101]. In the

present study, sample size limited our ability to assess trimester differences, with 6/7

pregnant females enrolled in our study being vaccinated in the second trimester of

pregnancy. Additionally, while race is an important consideration to understand differences

in immune responses to vaccination, small sample size has limited our ability to stratify

data in this way. Consideration of these demographic factors, among others is important

and should be a focus of future studies. The small sample size is a major limitation of this

study and was associated with challenges recruiting pregnant women. While 232 pregnant

women were approached during the study enrollment window, only 7 completed the study.

This likely reflects the limited COVID-19 vaccine uptake among pregnant women, which we

show is caused by numerous factors across the care continuum that contribute to COVID-

19 vaccine hesitancy in this population. Identification of points of public-health

intervention to effectively increase vaccine uptake among pregnant women is needed.

Methods

Study Design

Pregnant women were enrolled into mRNA vaccine studies at the Johns Hopkins Maternal

& Fetal Medicine Clinic (IRB 00246472) (n=7 pregnant) during the 2022-2023 vaccination

season. Pregnant women were contacted at clinical visits or via phone to determine

interest and eligibility. Women were eligible if they planned to receive an mRNA COVID

booster vaccine (Pfizer of Moderna) during weeks 32 through 36 of pregnancy, and consent

to maternal blood collection before and after receipt of the booster vaccine. Patients who

had already received an initial dose(s) of the vaccine were still eligible to enroll.

Participants were made aware of the study scope and the anonymity and confidentiality of

their collected data. The voluntary nature of their participation, and the details of the study

protocol were made evident. All participants gave informed consent to participate in the

study. Throughout recruitment, 232 pregnant women were approached to participate in this

study. Ninety-one patients were initially interested while only 14 enrolled in the study. Of

these, 7 completed the study. Of these seven, two women (distinguished by triangles in all

graphs) received monovalent ancestral boosters while the remaining five were recruited

after the release of the bivalent ancestral BA.5 booster in August of 2023 and thus received

this updated vaccine. For non-pregnant female comparators, samples were obtained from

age-matched adult female healthcare workers who were recruited during the 2022-2023

influenza vaccine enrollment period by fliers, emails, and announcements about the

annual vaccination program and were able to self-enroll upon receipt of the influenza

vaccine at the Johns Hopkins East Baltimore hospital (IRB00288258) (n = 13 non-pregnant).

All non-pregnant comparators selected as controls for this study received the bivalent

ancestral BA.5 booster vaccine. While we have documentation on the vaccine type

received at enrollment, prior vaccination and infection records were not available for

pregnant nor non-pregnant participants. Demographic information is detailed in **Table 1**. Of

the vaccinees enrolled, 13 age-matched non-pregnant females received the COVID-19

booster vaccine during the same vaccination season and had pre- and post-vaccination

blood samples available. Plasma and peripheral blood mononuclear cells were obtained

prior to and one month after receipt of mRNA booster vaccines from pregnant and non-

pregnant females. Plasma was used to assess antigen-specific immunoglobulin isotype

responses and neutralizing antibody responses, in addition to the crystallizable fragment

(Fc) receptor binding and non-neutralizing antibody functions. Cryopreserved PBMCs were

used for flow-cytometry analyses.

Cells and Viruses

VeroE6-TMPRSS2 cells were obtained from the cell repository of the National

Institute of Infectious Diseases, Japan, and were grown in complete medium consisting of

Dulbecco's modified Eagle's medium (DMEM) (Gibco, Thermo Fisher Scientific),

containing 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific), 1 mM glutamine

(Invitrogen, Thermo Fisher Scientific), 1 mM sodium pyruvate (Invitrogen, Thermo Fisher

Scientific), 100 U/mL penicillin (Invitrogen, Thermo Fisher Scientific), and 100 µg/mL

streptomycin (Invitrogen, Thermo Fisher Scientific). Cells were incubated at 37°C in a

humidified incubator with 5% CO_2.

Ancestral (hCoV-19/USA/DC-HP00007/2020; B.1, GISAID EPI_ISL_434688), BA.5

(hCoV-19/USA/MD-HP32103-PIDCNSQVGY/2022, GISAID EPI_ISL_15013106), XBB.1.5

(hCoV-19/USA/MD-HP40900-PIDYSWHNUB/2022, GISAID EPI_ISL_16026423), and JN.1

(hCoV-19/USA/MD-HP49672-PIDDVSVURS/2023, GISAID EPI_ISL_18623285) variants of

SARS-CoV-2 were isolated in VeroE6-TMPRSS2 cells plated in 24-well plates as previously

described [35]. The consensus sequence of the virus isolate did not differ from the

sequence derived from the clinical specimen. The infectious virus titer was determined on

Vero-E6-TMPRSS2 cells using a 50% tissue culture infectious dose (TCID50) assay as

described [36].

Microneutralization assays

Plasma neutralizing antibodies [37] were determined as described for SARS-CoV

and modified for SARS-CoV-2 as described [38]. Two-fold dilutions of plasma, starting at a

1:20 dilution, were made using incomplete medium (IM) - Dulbecco's modified Eagle's

medium (DMEM) (Gibco, Thermo Fisher Scientific), containing 1 mM glutamine (Invitrogen,

Thermo Fisher Scientific), 1 mM sodium pyruvate (Invitrogen, Thermo Fisher Scientific), 100

U/mL penicillin (Invitrogen, Thermo Fisher Scientific), and 100 µg/mL streptomycin

(Invitrogen, Thermo Fisher Scientific). Infectious virus was added to the plasma dilutions at

a final concentration of 1 × 10^3 TCID50/mL or 100 TCID50 per 100 µL. The plasma-virus

solution was incubated at room temperature for 1 hour, and 100 µL of each dilution was

added to 1 well of a 96-well plate of VeroE6-TMPRSS2 cells in hextuplicate. The cells were

incubated for 6 hours at 37°C with 5% CO_2. The inoculum was replaced with fresh IM, and

the cells were incubated at 37°C with 5% CO_2 for 3-4 days until cytopathic effect (CPE) is

evident in the no serum controls. The cells were fixed by the addition of 100 µL of 4%

formaldehyde for at least 4 hours at room temperature and then stained with naphthol

blue-black overnight. The nAb titer was calculated as the highest serum dilution that

eliminated the CPE in 50% of the wells (NT50), and the AUC was calculated [39, 40].

Antigen-bead coupling

Antigen-specific isotyping and Fc-receptor binding were multiplexed using a

Luminex Intelliflex in a 384-well format. Antigens used in this panel are as follows:

ancestral spike (S) and nucleocapsid (N) protein, BA.5, XBB.1.5, and JN.1 spike proteins.

These were obtained through the National Cancer Institute Serological Sciences Networks

(SeroNet) for COVID-19 [41]. Each antigen was coupled to unique MagPlex bead regions

(Luminex). Briefly, beads were activated by combining activation buffer (0.1M NaH2PO4;

pH 6.2), 50mg/mL 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC), and 50mg/mL

Sulfo-NHS (N-hydroxysulfosuccinimide). Activated beads were coupled to 25µg of antigen

in coupling buffer (0.05M MES; pH 5.0). Activated coupled beads were blocked with

blocking buffer (PBS 1X, 0.1% BSA, 0.02% Tween-20, 0.05% sodium azide; pH 7.4), washed

with washing buffer (PBS 1X, 0.05% Tween-20) and stored at 4°C in PBS.

Luminex serological assays

Serum was diluted 1:25 and was incubated with bead solution (20 µL of each bead

region in 20 mL of Luminex Assay Buffer: PBS 1X, 0.1% BSA, 0.05% Tween-20). This

protocol was followed for isotyping (IgM, IgG [IgG1-4], and IgA [IgA1-2]) and binding to the

following Fc receptors (FcRs): FcγRIIA-R, FcγRIIA-H, FcγRIIb, FcγRIIIA-V, FcγRIIIA-F,

FcγRIIIB, FcRn, and FcαR (Duke Vaccine Institute – Protein Production facility). Following

incubation, plates were placed on a magnet and washed with Procartaplex Wash Buffer

(ThermoFisher). Each assay plate was then incubated with 45 µL of secondary antibody

diluted in Luminex Assay Buffer. Isotypes were identified by PE-conjugated antibodies

(Southern Biotech) and FcR proteins were biotinylated using BirA biotin-ligation kit (Avidity)

at least one day prior and coupled to PE-Streptavidin (BioLegend) for 15 min on a rotor

before use. Following incubation with secondary antibody, plates were placed on a magnet

and washed. Beads were resuspended in Procartaplex Wash Buffer before running on the

Luminex Intelliflex. Samples were run on FlexMap 3D Low with a DD range of 7000-1700.

For each assay, a minimum of 100 events was recorded per antigen and the MFI of

secondary antibody-conjugated to PE, or FcR protein-conjugated to PE for each bead

region was measured to quantify antigen-specific immunoglobulin isotypes and FcR

responses in each sample at 0- and 28-days post vaccination [42]. LOB (limit of

background) for these assays was set by PBS and IgG depleted sera as a negative control.

Additional positive controls were included to ensure assay integrity. Optimal serum dilution

was determined by a dilution curve to ensure all values fell within the limit of detection.

Antibody-dependent complement deposition (ADCD)

Serum (1:15 dilution) was added to MagPlex antigen coated beads. Plates were

incubated, placed on a magnet, and washed 3 times with 1% BSA. Lyophilized Low-Tox

Guinea Pig Complement (Cedarlane) was reconstituted in ice-cold dH2O and diluted 1:25

in Gelatin Veronal buffer with Mg^{2+} & Ca^{2+} (GVB++) (Boston Bio). Diluted complement

protein was added to each well followed by incubation at 37C. IgG goat anti-guinea pig C3

(MP Biomedicals) was diluted 1:500 in 0.1% BSA and added to each well. After incubation,

Donkey-anti goat IgG secondary antibody-PE (ThermoFisher) was diluted 1:200 in 0.1% BSA

and added to each well. Beads were resuspended in 0.1% BSA and run on the Luminex

Intelliflex and data was collected as described above.

Antibody-dependent NK-cell cytotoxicity (ADNK)

Natural killer (NK) cells were isolated from donor blood. Whole blood was

centrifuged through a Ficoll gradient to harvest PBMCs and NK cells were isolated from

PBMCs using the MagniSort™ Human NK-cell Enrichment Kit (ThermoFisher). Cell

concentration was normalized to 1.5 x 10^6 cells/mL in R10 medium, and IL-15 (1 ng/mL,

Abcam) was added and incubated overnight at 37°C. Plates were coated with 3 mg/mL

antigen (ancestral, BA.5, XBB.1.5, and JN.1 spike proteins – SeroNet), blocked with 5%

BSA, washed, and dried before adding serum (1:100 dilution). Inhibitor cocktail (2.5 µL

CD107a-PeCy5 (BD Bioscience - BDB555802) + 0.5 mL BFA (Millipore Sigma) + 1 µL Golgi

Stop (BD Bioscience) + 9 mL R10 medium) was added to each well, incubated, and surface

staining cocktail (1 µL CD3-Pacific Blue (BD Bioscience - BDB558117) + 1mL CD56-PE-Cy7

(BD Bioscience - BDB557747) + 1 mL CD16-APC-Cy7 (BD Bioscience - BDB557758) + 7 mL

PBS) is added to a V-bottom 96-well plate. NK cells were transferred to the V-bottom 96

well plate with pre-added surface stain cocktail and incubated. Cells were pelleted,

supernatant removed, and Perm A (ThermoFisher) was added to each well. Cells were

washed and Intracellular staining cocktail (1 mL IFNγ-APC (BD Bioscience -) + 1 mL MIP1-

B-PE (BD Bioscience -BDB550078)   + 48 mL Perm B (ThermoFisher) was added to each

well. Plates were washed, cells were resuspended in PBS and run on a Symphony A3

through the Bloomberg Flow Cytometry and Immunology Core. Gating strategy as follows:

NK cells- CD3-, CD16+, CD56+ with reported cell populations including IFNγ+, CD107a+

and MIP-1β + NK cells.

Antibody-dependent neutrophil phagocytosis (ADNP)

531   Antigens (ancestral, BA.5, XBB.1.5, and JN.1 spike proteins – SeroNet) were

biotinylated with the BirA biotin-ligation kit (Avidity) and coupled to FluoSpheres™

NeutrAvidin™-Labeled Microspheres, 1.0 µm, yellow-green fluorescent (505/515)

(ThermoFisher). Antigen was combined with NeutrAvidin beads and incubated. Serum was

diluted 1:100 in PBS and incubated with antigen coated beads. During incubation, cells

were isolated from donor blood. Whole blood was collected into CPT tubes and centrifuged

at 1000 rpm for 30 min. Granulocytes were collected from below the density gradient. Cells

were suspended 1:10 in ACK Lysis buffer and incubated at RT for 5 min to lyse red blood

cells. Cells were washed and resuspended in 10 mL of PBS. Plates were washed with PBS,

200µL of neutrophil solution (5 x 10^6 cells/plate) was added to each well, incubated, spun

at 500g for 5 min, and cells were resuspended in extracellular staining solution (0.5µL APC

CD66b (BioLegend - 305117) + 19.5mL PBS / well) and incubated for 15min covered with

foil at RT. After staining, plates were washed and resuspended in 4% PFA to fix cells,

washed and resuspended in PBS. Plates were run on the Attune NxT flow cytometer. Gating

on CD66b+ cells (neutrophils) followed by bead+ neutrophils, stained with APC. Data are

reported as a PhagoScore, calculated as (% bead-positive neutrophils) * (geometric MFI of

each cell) [43].

Antibody-dependent cellular phagocytosis (ADCP)

THP-1 cells, a human monocytic cell line, were grown in suspension and diluted

with warm R10 medium. Following immune complex formation, assay plates are washed

with PBS and centrifuged at 2000g for 10 min. The THP-1 cells were plated 2.5 x 10^4 per

well, and incubated O/N at 37°C. THP-1 cells were fixed, washed, and resuspended in PBS.

Plates are run on the Attune NxT flow cytometer. Gating included bead+ single-cells

stained with APC, representing THP-1 cells that have phagocytosed bead. Data are

reported as a PhagoScore, calculated as (% bead-positive THP-1) * (geometric MFI of each

cell) [44].

Ex vivo flow cytometry staining

Intracellular cytokine-flow cytometry staining was used to assess antigen-specific

cytokine production and T-cell phenotypic and functional profiles. Cryopreserved PBMCs

were thawed, rested, and cultured overnight with 1 mg/mL peptide pools consisting of 315

peptides (15-mers with 11 amino acid overlap) spanning the ancestral SARS-CoV-2 spike

protein (JPT Peptide Technologies, PM-WCPV-S-1) or a DMSO (unstimulated) control. After

overnight incubation, cells were washed and stained for viability with Invitrogen Live/Dead

Fixable Blue Dead Cell Stain (L34962) and Fc Block (564219). Cell-surface staining was

performed with our T-cell panel surface-antibody cocktail mix (**Supplementary Methods**

Table 1A). Cells were fixed and permeabilized with a 1X Fixation/Permeabilization buffer

from eBioscience (FoxP3/Transcription Factor Staining Buffer Set). Intracellular staining

was performed with intracellular cytokine-antibody cocktail mix (**Supplementary Methods**

Table 1B). Cells were resuspended in 1% paraformaldehyde and run on the 4-laser (16UV-

16V-15B-8R) Cytek Biosciences Aurora spectral flow cytometer. For ICS, data were

processed using biexponential transformation and exported for further analysis in FlowJo to

assess cytokine-producing, antigen-specific T cells (**Supplemental Figure 3-4**).

Polyfunctionality of these T cells was analyzed with Pestle v2.0 and SPICE 6 v6.1.

Metabolic, activation, and exhaustions markers were analyzed via Uniform Manifold

Approximation and Projection (UMAP) (v4.1.1), Xshift (v1.4.1), and ClusterExplorer (v1.7.6).

Statistical analyses

GraphPad Prism v10.1 was used to perform univariate analyses with details about

statistical tests used for each dataset described in further detail in figure legends.

Spearman correlations of systems serology measures were visualized in heatmaps

generated using R v4.2.3 and version 1.0.12 of the package "pheatmap" (https://cran.r-

[project.org/web/packages/pheatmap](https://cran.r-project.org/web/packages/pheatmap)[45]. For ADNP and ADNK assays, data were

averaged across two healthy donors. Flow FCS files were analyzed using FlowJo v10

(10.8.1) software. Gating strategy for ICS can be found in **Supplementary Figures 3** and **4**.

ICS data were exported from Pestle v2.0 and SPICE 6 v6.1 for further statistical analyses

detailed in figure legends.

Data Availability

All anonymized data that support the findings of this study can be made available upon

request from the corresponding author.

Acknowledgements. We thank the clinical coordinators and vaccinees for making this

study possible. We are especially grateful to Kimberly Jones-Beatty and Michelle Ufua for

their assistance with recruitment. Thank you to Galit Alter, Ryan McNamara, and Taras

Chicz for graciously training lab members and sharing protocols to develop systems

serology methods. We thank Prakash Srinivasan for the use of the Attune Nxt flow

cytometer and the Bloomberg Flow Cytometry and Immunology Core. This study was

supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and

Human Services (HHS) as part of a financial assistance award [Center of Excellence in

Regulatory Science and Innovation grant to Johns Hopkins University, U01FD005946]

totaling $415,256 with 75% percentage funded by FDA/ OWH. The contents are those of the

author(s) and do not necessarily represent the official views of, nor an endorsement, by

FDA/OWH, or the U.S. Government. FDA CERSI U01FD005942 (SLK), NIH NIAID

75N93021C00045 (AP, RR), NIH NCI U54 CA260492 (SLK, ALC).

Author Contributions

SLK, IB, AP, and ALC conceptualized the experimental design and group comparisons for

this study. MAP, H-SP, JSL, LStC, PS, IB, JS, KF, RR, and ALC identified, acquired, stored, and

distributed patient samples and clinical and demographic data for analyses. MAP, H-SP,

PC, AW and JSL developed and validated serological assays. MAP, JS, LG and H-SP

processed samples and completed technical assays. MAP, KR, and AY conducted

statistical analyses. MAP, LG, KR, ALC, and SLK developed all tables and figures. MAP, ALC,

SLK wrote the initial draft of the manuscript. MAP, JS, LG, HSP, AY, KR, PC, JSL, LAS, AW,

CPG, LB, HG, PS, KF, RR, IB, JS, ALC, AP, and SLC provided substantive edits and approved

the final draft of the manuscript.

χ2 = (5.642, 3), p = 0.13   χ2 = (6.353, 3), p = 0.09   χ2 = (7.190, 3), p = 0.06   χ2 = (8.039, 3), **p = 0.04**

Figure 1. Vaccination differently induces IgG subtype responses during pregnancy. IgG

antibody responses in serum pre and 3-5 weeks post-vaccination were measured by

systems serology and reported as $\log_{10}$ mean fluorescence intensity. Pregnant women (n=7)

are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight women

who received monovalent boosters and circles represent bivalent booster recipients.

Horizontal bars indicate mean MFI across samples with bars indicating standard error of

the mean. **(A)** Total IgG to ancestral nucleocapsid (N) protein. **(B)** Total IgG separated by

SARS-CoV-2 vaccine (ancestral and BA.5) and variant (XBB1.5 and JN.1) spike (S) antigen

and pregnancy status. **(C-F)** Relative abundance of IgG subtypes in pregnant and non-

pregnant women as stacked bar plots representing each isotype as a percentage of Total

IgG by **(C)** ancestral S, **(D)** BA.5 S, **(E)** XBB.1.5 S, and **(F)** JN.1 S. Data were analyzed by (A)

repeated measures two-way ANOVA (B) linear mixed effects regression analysis with

Bonferroni post-hoc. (C-F) Isotype proportions were analyzed by Chi-squared analysis with

values reported under each corresponding graph. Asterisks indicate p< 0.05. Stippled line

indicates limit of background (LOB) defined as the $\log_{10}$MFI of a defined negative control.

Figure 2. Pregnancy alters cross-neutralization of variants of concern. IgG antibody

responses in serum pre and 3-5 weeks post-vaccination were measured by systems

serology and reported as mean fluorescence intensity. Pregnant women (n=7) are shown in

orange and non-pregnant females (n=13) in purple. Triangles highlight women who received

monovalent boosters and circles represent bivalent booster recipients. Bars represent

mean MFI across samples with bars indicating standard error of the mean. **(A-E)** Ratio of

IgG1:IgG3 antibodies specific to **(A)** ancestral spike (S), **(B)** BA.5 S, **(C)** XBB.1.5 S, and **(D)**

JN.1 S. Neutralizing antibody titers reported as Log_2 NT50 against **(E)** ancestral, **(F)** BA.5, **(G)**

XBB.1.5, and **(H)** JN.1 viruses. Ratios shown on the x-axis indicate number of women per

group/timepoint that are above the limit of detection (LOD) indicated by the stippled line. **(I-**

L) Pearson correlations between IgG1:IgG3 ratios and neutralizing antibody titers reported

as Log_2 NT50 to **(I)** ancestral spike (S), **(J)** BA.5 S, **(K)** XBB.1.5 S, and **(L)** JN.1 S. (A-H) Data

were analyzed by repeated measures two-way ANOVA with Bonferroni post-hoc. Asterisks

indicate p< 0.05. (I-L) Regression lines for each group are shown in dashed lines colored

according to cohort. Separate R^2 and p-values are shown for each variant separated by

pregnancy status.

Figure 3. Fc receptor binding is reduced in pregnant women in response to variants of concern. Serum antibody Fc receptor (FcR) binding pre and 3-5 weeks post-vaccination were measured by multiplex Luminex bead assays and reported as $\log_{10}$ mean fluorescence intensity. Pregnant women (n=7) are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight women who received monovalent boosters and circles represent bivalent booster recipients. Horizontal bars indicate mean MFI across samples with bars indicating standard error of the mean. Antibody binging to FcγRIIA-R, FcγRIIA-H, FcγRIIb, FcγRIIIA-V, FcγRIIIA-F, FcγRIIIB, FcRn, and FcαR was determined for **(A)** ancestral spike (S), **(B)** BA.5 S, **(C)** XBB.1.5 S, and **(D)** JN.1 S. Data were analyzed by linear mixed effects regression analysis with Bonferroni post-hoc. Asterisks indicate p< 0.05. Stippled line indicates limit of background (LOB) defined as the $\log_{10}$MFI of a defined negative control.

Figure 4. Non-neutralizing and neutralizing antibody functions are negatively

correlated among pregnant women. Non-neutralizing antibody functions were measured

pre and 3-5 weeks post-vaccination. Pregnant women (n=7) are shown in orange and non-

pregnant females (n=13) in purple. Triangles highlight women who received monovalent

boosters and circles represent bivalent booster recipients. Horizontal bars indicate mean

MFI across samples with bars indicating standard error of the mean. **(A)** antibody

dependent complement deposition (ADCD) was measured by assessing antibody binding

to C3 protein and is reported as $\log_{10}$ mean fluorescence intensity. Stippled line indicates

limit of background (LOB) defined as the $\log_{10}$MFI of a defined negative control. NK cells

isolated from donor blood were utilized to assess **(B)** antibody dependent NK cell

cytotoxicity (ADNK), or the ability of antigen specific serum antibody to include NK cell

cytokine production or degranulation. Data are reported as % MIP1B+ cells of

CD16+/CD56+ NK cells. **(C)** THP-1 monocyte cell line was used to measure antibody

dependent cellular phagocytosis (ADCP), or the ability of antibody to induce phagocytosis

of antigen. **(D)** Neutrophils isolated from donor blood were used to measure antibody

dependent neutrophil phagocytosis (ADNP), or the ability of antibody to induce neutrophil

phagocytosis of antigen. ADCP and ADNP are reported as a PhagoScore, calculated as (%

bead positive monocytes/neutrophils) * (geometric MFI of each cell). **(E-H)** Pearson

correlations between post-vaccination neutralizing antibody titers ($\log_2$NT50) and ADNP

PhagoScores for are shown for: **(E)** ancestral, **(F)** BA.5, **(G)** XBB.1.5, and **(H)** JN.1 viruses. (A-

E) Data were analyzed by linear mixed effects regression analysis with Bonferroni post-hoc

with asterisks indicating $p < 0.05$. (E-H) Separate Pearson correlation R^2 and p-values are

shown for each variant separated by pregnancy status, with $p < 0.05$ shown in bolded font.

Regression lines for each group are shown in dashed lines colored according to cohort.

Figure 5. Correlations among IgG subclasses and antibody functional phenotypes

differ between pregnant and nonpregnant women. (A) Pre-vaccination and **(B)** post-

vaccination systems serology measures including isotype subclasses, FcR binding, non-

neutralizing functions, and neutralizing antibody titers were log$_{10}$ transformed and used for

Spearman correlation analyses. Isotypes (y-axis) were correlated with functional measures

(x-axis). Analyses were performed by pregnancy status. Asterisks indicate p< 0.05. Colors

indicate Spearman correlation R value with a positive correlation of 1 indicated by deep red

and a negative correlation of 1 indicated by deep blue. Abbreviations defined as followed:

ADNP – antibody dependent neutrophil phagocytosis; ADCP – antibody dependent cellular

phagocytosis; ADNK – antibody dependent NK cell cytotoxicity; ADCD – antibody

dependent complement deposition; NT – neutralizing antibody titer.

Figure 6. CD4+ T cells have reduced polyfunctionality among pregnant women.

Peripheral blood mononuclear cells (PBMCs) were collected pre and 3-5 weeks post-

vaccination for flow cytometry analyses. Cytokine-producing, antigen-specific CD4+ T cells

for **(A)** pregnant (n=7) and **(B)** non-pregnant (n=3) women represented in pie charts broken

down by the 15 cytokine combination categories. Arcs identify portions of the pie that

express each specific cytokine**.** Paired dot plots demonstrate the percent of memory CD4+

T cell producing **(C)** IFNγ, **(D)** TNF, **(E)** IL-2, or **(F)** IL-21 following stimulation with ancestral

SARS-CoV-2 spike peptide pools pre- and post-vaccination. Data were analyzed by linear

mixed effects regression analysis with Bonferroni post-hoc. Asterisks indicate p< 0.05.

 Figure 7. Carnitine palmitoyl transferase 1A (CPT1a) expression in CD4+ and CD8+ T

cells pre- and post-vaccination is higher in pregnant women. Peripheral blood

mononuclear cells (PBMCs) were collected pre and 3-5 weeks post-vaccination for flow

cytometry analyses. Histograms showing CPT1a expression in total **(A)** CD4[+] and **(C)** CD8[+] T

cells from peripheral blood mononuclear cells collected pre- and 3–5 weeks post-

vaccination. Pregnant individuals (n=7) are shown in orange and non-pregnant individuals

(n=3) in purple. Quantification of mean fluorescence intensity in memory CD4[+] **(B)** and

memory CD8+ **(D)** T cells are shown for each group pre- and post-vaccination. Horizontal

bars indicate mean MFI across samples with bars indicating standard error of the mean.

Data were analyzed by linear mixed effects regression analysis with Bonferroni post-hoc.

Asterisks indicate $p < 0.05$.

Table 1.

	Non-Pregnant n = 10	Pregnant n = 7	P-Value
Demographics	Mean $\pm$ SD	Mean $\pm$ SD	
Age	31.8 $\pm$ 3.35	32.9 $\pm$ 3.18	0.5243734
Vaccine Type	0 0%	2 28.5%	
Monovalent Booster	10 100%	5 71.5%	
Bivalent Booster			
Average Gestational Age (weeks)	-	22.4 $\pm$ 11.78	
	N %	N %	
Race			
White	6 60.0%	7 100%	
Black	2 20.0%	0 0%	
Asian	2 20.0%	0 0%	
Gestational Age (At Vaccination)	-	1st Trimester (n = 0) 0% 2nd Trimester (n = 6) 85.8% 3rd Trimester (n = 1) 14.2%	

References

1. Engjom, H.M., et al., *Perinatal outcomes after admission with COVID-19 in pregnancy: a UK national cohort study.* Nature Communications, 2024. **15**(1): p. 3234.
2. Brioschi Dos Santos, A.P., et al., *The impact of COVID-19 on maternal death and fetal death, a cohort study in Brazil.* PLoS One, 2023. **18**(8): p. e0290343.
3. St Clair, L.A., et al., *Reduced control of SARS-CoV-2 infection associates with lower mucosal antibody responses in pregnancy.* mSphere, 2024. **9**(3): p. e0081223.
4. Strid, P., et al., *Coronavirus Disease 2019 (COVID-19) Severity Among Women of Reproductive Age With Symptomatic Laboratory-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Pregnancy Status-United States, 1 January 2020-25 December 2021.* Clin Infect Dis, 2022. **75**(Suppl 2): p. S317-s325.
5. Wei, S.Q., et al., *The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis.* Cmaj, 2021. **193**(16): p. E540-e548.
6. Sessa, R., et al., *SARS-CoV-2 Infection in Pregnancy: Clues and Proof of Adverse Outcomes.* Int J Environ Res Public Health, 2023. **20**(3).
7. Garcia-Flores, V., et al., *Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2.* Nat Commun, 2022. **13**(1): p. 320.
8. Verma, S., E.B. Carter, and I.U. Mysorekar, *SARS-CoV2 and pregnancy: An invisible enemy?* Am J Reprod Immunol, 2020. **84**(5): p. e13308.
9. Doss, J.D., et al., *A prospective cohort study of pregnancy outcomes following antepartum infection with SARS-CoV-2.* Pregnancy Hypertens, 2024. **37**: p. 101152.
10. Creisher, P.S., et al., *Adverse outcomes in SARS-CoV-2-infected pregnant mice are gestational age-dependent and resolve with antiviral treatment.* J Clin Invest, 2023. **133**(20).
11. Ciapponi, A., et al., *Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.* Vaccine, 2023. **41**(25): p. 3688-3700.
12. Razzaghi, H., et al., *COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.* Vaccine, 2022. **40**(32): p. 4554-4563.
13. CDC. *COVID-19 Vaccination Coverage, Pregnant Women, United States.* 2025 March 19 [cited 2025; Available from: https://www.cdc.gov/covidvaxview/weekly-dashboard/pregnant-persons-vaccination.html.
14. Razzaghi H, K.K., Calhoun K, et al., *Influenza, Tdap, and COVID-19 Vaccination Coverage and Hesitancy Among Pregnant Women — United States, April 2023.* MMWR Morb Mortal Wkly Rep, 2023.
15. Katherine E. Kahn, E.G., Hilda Razzaghi, Tara C. Jatlaoui, Tami H. Skoff, Sascha R. Ellington, Carla L. Black, *Flu, Tdap, and COVID-19 Vaccination Coverage Among Pregnant Women – United States, April 2024.* 2024.
16. Norman, M., et al., *Neonatal Outcomes After COVID-19 Vaccination in Pregnancy.* Jama, 2024. **331**(5): p. 396-407.

770   17.   CDC. *COVID-19 Vaccination for Women Who Are Pregnant or Breastfeeding*. 2024
771   September 10, 2024; Available from:
772   https://www.cdc.gov/covid/vaccines/pregnant-or-
773   breastfeeding.html#:~:text=COVID%2D19%20vaccination%20during%20pregnancy
774   ,19%20before%20or%20during%20pregnancy.
775   18.   Kumar, D., S. Verma, and I.U. Mysorekar, *COVID-19 and pregnancy: clinical
776   outcomes; mechanisms, and vaccine efficacy.* Transl Res, 2023. **251**: p. 84-95.
777   19.   Casubhoy, I., et al., *A scoping review of global COVID-19 vaccine hesitancy among
778   pregnant persons.* npj Vaccines, 2024. **9**(1): p. 131.
779   20.   Oliver, J., et al., *Drivers of COVID-19 vaccine hesitancy among women of
780   childbearing age in Victoria, Australia: A descriptive qualitative study.* Vaccine: X,
781   2022. **12**: p. 100240.
782   21.   Hsu, A.L., et al., *Sources of Vaccine Hesitancy: Pregnancy, Infertility, Minority
783   Concerns, and General Skepticism.* Open Forum Infectious Diseases, 2021. **9**(3).
784   22.   Shephard HM, M.S., Nestoridi E, et al. *Inequities in COVID-19 Vaccination Coverage
785   Among Pregnant Persons*. MMWR Morb Mortal Wkly Rep 2023 September 29, 2023.
786   23.   Anderson, M.R., E.J. Hardy, and C.L. Battle, *COVID-19 Vaccine Hesitancy during the
787   Perinatal Period: Understanding Psychological and Cultural Factors to Improve Care
788   and Address Racial/Ethnic Health Inequities.* Womens Health Issues, 2022. **32**(4): p.
789   317-321.
790   24.   Ramonfaur, D., et al., *Determinants of COVID-19 vaccine hesitancy among pregnant
791   persons.* J Am Pharm Assoc (2003), 2023. **63**(4): p. 1191-1196.
792   25.   Chavan, M., et al., *COVID-19 Vaccination in Pregnancy: The Benefits Outweigh the
793   Risks.* J Obstet Gynaecol Can, 2021. **43**(7): p. 814-816.
794   26.   Kay, A.W. and C.A. Blish, *Immunogenicity and Clinical Efficacy of Influenza
795   Vaccination in Pregnancy.* Front Immunol, 2015. **6**: p. 289.
796   27.   Chayachinda, C., et al., *Immunogenicity and reactogenicity of heterologous COVID-
797   19 vaccination in pregnant women*. Hum Vaccin Immunother, 2023. **19**(2): p.
798   2228670.
799   28.   Ballivian, J., et al., *Immunogenicity of COVID-19 Vaccines During Pregnancy: A
800   Systematic Review and Comparison of Pregnant Versus Nonpregnant Persons.*
801   Pediatr Infect Dis J, 2025. **44**(2s): p. S27-s31.
802   29.   hemati, Z., et al., *Comparing the immunogenicity of COVID-19 infection and
803   vaccination in pregnant women as measured by anti-S IgG.* BMC Infectious
804   Diseases, 2024. **24**(1): p. 935.
805   30.   Munoz, F.M., et al., *COVID-19 booster vaccination during pregnancy enhances
806   maternal binding and neutralizing antibody responses and transplacental antibody
807   transfer to the newborn.* Vaccine, 2023. **41**(36): p. 5296-5303.
808   31.   Lopez, P.A., et al., *Placental transfer dynamics and durability of maternal COVID-19
809   vaccine-induced antibodies in infants.* iScience, 2024. **27**(3): p. 109273.
810   32.   Cassidy, A.G., et al., *Assessment of Adverse Reactions, Antibody Patterns, and 12-
811   month Outcomes in the Mother-Infant Dyad After COVID-19 mRNA Vaccination in
812   Pregnancy.* JAMA Netw Open, 2023. **6**(7): p. e2323405.

33.   Atyeo, C., et al., *COVID-19 mRNA vaccines drive differential antibody Fc-functional*
profiles in pregnant, lactating, and nonpregnant women. Sci Transl Med, 2021.
13(617): p. eabi8631.
34.   Ackerman, M.E., D.H. Barouch, and G. Alter, *Systems serology for evaluation of HIV*
vaccine trials. Immunol Rev, 2017. **275**(1): p. 262-270.
35.   Fall, A., et al., *The displacement of the SARS-CoV-2 variant Delta with Omicron: An*
investigation of hospital admissions and upper respiratory viral loads. EBioMedicine,
2022. **79**: p. 104008.
36.   Dhakal, S., et al., *Sex Differences in Lung Imaging and SARS-CoV-2 Antibody*
Responses in a COVID-19 Golden Syrian Hamster Model. mBio, 2021. **12**(4): p.
e0097421.
37.   Dhakal, S., et al., *Reconsideration of Antinucleocapsid IgG Antibody as a Marker of*
SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients. Open Forum
Infect Dis, 2023. **10**(1): p. ofac677.
38.   Lee, J.M., et al., *Three doses of COVID-19 mRNA vaccine induce class-switched*
antibody responses in inflammatory arthritis patients on immunomodulatory
therapies. Front Immunol, 2023. **14**: p. 1266370.
39.   Li, M., et al., *Convalescent plasma with a high level of virus-specific antibody*
effectively neutralizes SARS-CoV-2 variants of concern. Blood Adv, 2022. **6**(12): p.
3678-3683.
40.   Klein, S.L., et al., *Sex, age, and hospitalization drive antibody responses in a COVID-*
19 convalescent plasma donor population. J Clin Invest, 2020. **130**(11): p. 6141-
6150.
41.   Karger, A.B., et al., *The Serological Sciences Network (SeroNet) for COVID-19: Depth*
and Breadth of Serology Assays and Plans for Assay Harmonization. mSphere, 2022.
7(4): p. e0019322.
42.   Chung, A.W., et al., *Dissecting Polyclonal Vaccine-Induced Humoral Immunity*
against HIV Using Systems Serology. Cell, 2015. **163**(4): p. 988-98.
43.   Karsten, C.B., et al., *A versatile high-throughput assay to characterize antibody-*
mediated neutrophil phagocytosis. J Immunol Methods, 2019. **471**: p. 46-56.
44.   Loos, C., et al., *Systems serology-based comparison of antibody effector functions*
induced by adjuvanted vaccines to guide vaccine design. npj Vaccines, 2023. **8**(1): p.
34.
45.   Kolde, R., *Pretty Heatmaps.* 2018. p. Implementation of heatmaps that offers more
control over dimensions and appearance.
46.   Gaeta, A., et al., *Anti-N SARS-CoV-2 assays for evaluation of natural viral infection.* J
Immunol Methods, 2023. **518**: p. 113486.
47.   Swadźba, J., et al., *High Concentration of Anti-SARS-CoV-2 Antibodies 2 Years after*
COVID-19 Vaccination Stems Not Only from Boosters but Also from Widespread,
Often Unrecognized, Contact with the Virus. Vaccines (Basel), 2024. **12**(5).
48.   Uversky, V.N., et al., *IgG4 Antibodies Induced by Repeated Vaccination May*
Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines (Basel),
2023. **11**(5).

49.   Subramanian, S.V. and A. Kumar, *Increases in COVID-19 are unrelated to levels of*
857   *vaccination across 68 countries and 2947 counties in the United States.* Eur J
858   Epidemiol, 2021. **36**(12): p. 1237-1240.
859   50.   Chen, W., et al., *The kinetics of IgG subclasses and contributions to neutralizing*
860   *activity against SARS-CoV-2 wild-type strain and variants in healthy adults*
861   *immunized with inactivated vaccine.* Immunology, 2022. **167**(2): p. 221-232.
862   51.   Sun, K., et al., *SARS-CoV-2 correlates of protection from infection against variants of*
863   *concern.* Nature Medicine, 2024. **30**(10): p. 2805-2812.
864   52.   Earle, K.A., et al., *Evidence for antibody as a protective correlate for COVID-19*
865   *vaccines.* Vaccine, 2021. **39**(32): p. 4423-4428.
866   53.   Flor, N., et al., *Antibodies to SARS-CoV2 induced by vaccination and infection*
867   *correlate with protection against the infection.* Vaccine, 2023. **41**(48): p. 7206-7211.
868   54.   Izadi, A. and P. Nordenfelt, *Protective non-neutralizing SARS-CoV-2 monoclonal*
869   *antibodies.* Trends Immunol, 2024. **45**(8): p. 609-624.
870   55.   Mackin, S.R., et al., *Fc-γR-dependent antibody effector functions are required for*
871   *vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2.* Nat
872   Microbiol, 2023. **8**(4): p. 569-580.
873   56.   Chandler, T.L., et al., *Protective mechanisms of nonneutralizing antiviral antibodies.*
874   PLoS Pathog, 2023. **19**(10): p. e1011670.
875   57.   Lu, Y., et al., *The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune*
876   *escape, and response strategies.* MedComm (2020), 2024. **5**(8): p. e675.
877   58.   Du, M.R., S.C. Wang, and D.J. Li, *The integrative roles of chemokines at the*
878   *maternal-fetal interface in early pregnancy.* Cell Mol Immunol, 2014. **11**(5): p. 438-
879   48.
880   59.   Bluman, E.M., et al., *Human natural killer cells produce abundant macrophage*
881   *inflammatory protein-1 alpha in response to monocyte-derived cytokines.* J Clin
882   Invest, 1996. **97**(12): p. 2722-7.
883   60.   Boudreau, C.M., et al., *Antibody-mediated NK cell activation as a correlate of*
884   *immunity against influenza infection.* Nature Communications, 2023. **14**(1): p. 5170.
885   61.   Lin, Q., et al., *IFN-γ-dependent NK cell activation is essential to metastasis*
886   *suppression by engineered Salmonella.* Nature Communications, 2021. **12**(1): p.
887   2537.
888   62.   Tortorici, M.A., et al., *Persistent immune imprinting occurs after vaccination with the*
889   *COVID-19 XBB.1.5 mRNA booster in humans.* Immunity, 2024. **57**(4): p. 904-911.e4.
890   63.   Atyeo, C., et al., *Distinct Early Serological Signatures Track with SARS-CoV-2*
891   *Survival.* Immunity, 2020. **53**(3): p. 524-532.e4.
892   64.   Sha, Z. and R.W. Compans, *Induction of CD4(+) T-cell-independent immunoglobulin*
893   *responses by inactivated influenza virus.* J Virol, 2000. **74**(11): p. 4999-5005.
894   65.   Thompson, E.A., et al., *Heterologous versus homologous boosting elicits*
895   *qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients.* JCI Insight,
896   2023. **8**(10).
897   66.   Roznik, K., et al., *COVID-19 vaccination induces distinct T-cell responses in*
898   *pediatric solid organ transplant recipients and immunocompetent children.* NPJ
899   Vaccines, 2024. **9**(1): p. 73.

67.   Boyd, A., et al., *Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell*
Efficacy and Immune Protection. PLoS One, 2015. **10**(6): p. e0128714.
68.   Darrah, P.A., et al., *Multifunctional TH1 cells define a correlate of vaccine-mediated*
protection against Leishmania major. Nat Med, 2007. **13**(7): p. 843-50.
69.   Rakshit, S., et al., *Polyfunctional CD4 T-cells correlating with neutralising antibody is*
a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19
exposed Indians. npj Vaccines, 2023. **8**(1): p. 134.
70.   Li, L., et al., *In-depth analysis of SARS-CoV-2-specific T cells reveals diverse*
differentiation hierarchies in vaccinated individuals. JCI Insight, 2022. **7**(7).
71.   Peng, S.L., S.J. Szabo, and L.H. Glimcher, *T-bet regulates IgG class switching and*
pathogenic autoantibody production. Proc Natl Acad Sci U S A, 2002. **99**(8): p. 5545-
50.
72.   Alspach, E., D.M. Lussier, and R.D. Schreiber, *Interferon γ and Its Important Roles in*
Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold
Spring Harb Perspect Biol, 2019. **11**(3).
73.   Mohr, E., et al., *IFN-{gamma} produced by CD8 T cells induces T-bet-dependent and*
-independent class switching in B cells in responses to alum-precipitated protein
vaccine. Proc Natl Acad Sci U S A, 2010. **107**(40): p. 17292-7.
74.   Ballesteros-Tato, A., et al., *Interleukin-2 inhibits germinal center formation by*
limiting T follicular helper cell differentiation. Immunity, 2012. **36**(5): p. 847-56.
75.   Pasparakis, M., et al., *Immune and inflammatory responses in TNF alpha-deficient*
mice: a critical requirement for TNF alpha in the formation of primary B cell follicles,
follicular dendritic cell networks and germinal centers, and in the maturation of the
humoral immune response. Journal of Experimental Medicine, 1996. **184**(4): p.
1397-1411.
76.   Elsner, R.A. and M.J. Shlomchik, *Germinal Center and Extrafollicular B Cell*
Responses in Vaccination, Immunity, and Autoimmunity. Immunity, 2020. **53**(6): p.
1136-1150.
77.   Xiong, J., *Fatty Acid Oxidation in Cell Fate Determination*. Trends Biochem Sci, 2018.
43(11): p. 854-857.
78.   Sewell, C.A., et al., *Scientific, ethical, and legal considerations for the inclusion of*
pregnant people in clinical trials. Am J Obstet Gynecol, 2022. **227**(6): p. 805-811.
79.   Jenkins, B.J., et al., *Does Altered Cellular Metabolism Underpin the Normal Changes*
to the Maternal Immune System during Pregnancy? Immunometabolism, 2021. **3**(4):
p. e210031.
80.   Atyeo, C.G., et al., *Maternal immune response and placental antibody transfer after*
COVID-19 vaccination across trimester and platforms. Nature Communications,
2022. **13**(1): p. 3571.
81.   Markov, P.V., et al., *The evolution of SARS-CoV-2*. Nature Reviews Microbiology,
2023. **21**(6): p. 361-379.
82.   Chi, W.Y., et al., *COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2*
variants, boosters, adverse effects, and immune correlates of protection. J Biomed
Sci, 2022. **29**(1): p. 82.

83.   Huiberts, A.J., et al., *Effectiveness of Omicron XBB.1.5 vaccine against infection*
944   *with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the*
945   *Netherlands, October 2023 to January 2024.* Euro Surveill, 2024. **29**(10).
946   84.   Rubin, R., *As COVID-19 Cases Surge, Here's What to Know About JN.1, the Latest*
947   *SARS-CoV-2 "Variant of Interest".* Jama, 2024. **331**(5): p. 382-383.
948   85.   CDC. *Staying Up to Date with COVID-19 Vaccines.* 2025 January 7, 2025 [cited 2025
949   March 25]; Available from: https://www.cdc.gov/covid/vaccines/stay-up-to-
950   date.html.
951   86.   Han, X. and Q. Ye, *The variants of SARS-CoV-2 and the challenges of vaccines.* J Med
952   Virol, 2022. **94**(4): p. 1366-1372.
953   87.   Cobey, S., et al., *Concerns about SARS-CoV-2 evolution should not hold back efforts*
954   *to expand vaccination.* Nat Rev Immunol, 2021. **21**(5): p. 330-335.
955   88.   Monto, A.S., A.S. Lauring, and E.T. Martin, *SARS-CoV-2 Vaccine Strain Selection:*
956   *Guidance From Influenza.* J Infect Dis, 2022. **227**(1): p. 4-8.
957   89.   Little D, B.E., Kibitel J, Carrico N, McNitt J. , *Which Comorbidities Increase the Risk*
958   *of a COVID-19 Breakthrough Infection?.* Epic Research. 2022.
959   90.   Regev-Yochay, G., et al., *Correlates of protection against COVID-19 infection and*
960   *intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2*
961   *in households in Israel (ICoFS): a prospective cohort study.* The Lancet Microbe,
962   2023. **4**(5): p. e309-e318.
963   91.   Goldblatt, D., et al., *Correlates of protection against SARS-CoV-2 infection and*
964   *COVID-19 disease.* Immunol Rev, 2022. **310**(1): p. 6-26.
965   92.   Mahrokhian, S.H., et al., *COVID-19 vaccines: Immune correlates and clinical*
966   *outcomes.* Hum Vaccin Immunother, 2024. **20**(1): p. 2324549.
967   93.   Rice, T.F., B. Holder, and B. Kampmann, *Antibody glycosylation in pregnancy and in*
968   *newborns: biological roles and implications.* Curr Opin Infect Dis, 2020. **33**(3): p.
969   225-230.
970   94.   Alter, G., T.H.M. Ottenhoff, and S.A. Joosten, *Antibody glycosylation in inflammation,*
971   *disease and vaccination.* Semin Immunol, 2018. **39**: p. 102-110.
972   95.   Adhikari, E.H., et al., *Diverging Maternal and Cord Antibody Functions From SARS-*
973   *CoV-2 Infection and Vaccination in Pregnancy.* J Infect Dis, 2024. **229**(2): p. 462-472.
974   96.   Kent, S.J., et al., *Disentangling the relative importance of T cell responses in COVID-*
975   *19: leading actors or supporting cast?* Nature Reviews Immunology, 2022. **22**(6): p.
976   387-397.
977   97.   Cai, F., S. Jin, and G. Chen, *The Effect of Lipid Metabolism on CD4(+) T Cells.*
978   Mediators Inflamm, 2021. **2021**: p. 6634532.
979   98.   Bulygin, A.S., et al., *The role of metabolism on regulatory T cell development and its*
980   *impact in tumor and transplantation immunity.* Front Immunol, 2022. **13**: p.
981   1016670.
982   99.   Stracuzzi, M., et al., *Short-lived neutralizing activity against SARS-CoV-2 in*
983   *newborns of immunized mothers.* Pediatr Allergy Immunol, 2025. **36**(4): p. e70084.
984   100.   Johnston, T.S., et al., *Immunological imprinting shapes the specificity of human*
985   *antibody responses against SARS-CoV-2 variants.* Immunity, 2024. **57**(4): p. 912-
986   925.e4.

987   101.   Yang, Y.J., et al., *Association of Gestational Age at Coronavirus Disease 2019*
988   *(COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus*
989   *2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical*
990   *Cord Antibody Levels at Delivery.* Obstetrics & Gynecology, 2022. **139**(3): p. 373-380.
991